Blend of ethylene and α-olefin copolymers obtained using a metallocene catalyst for fabricating medical films and tubings

Information

  • Patent Grant
  • 6372848
  • Patent Number
    6,372,848
  • Date Filed
    Tuesday, October 10, 2000
    23 years ago
  • Date Issued
    Tuesday, April 16, 2002
    22 years ago
Abstract
The present invention provides a polymer blend for fabricating medical products. The blend has a first ethylene and α-olefin copolymer obtained using a single-site catalyst present in an amount by weight of from about 0% to about 99% by weight of the blend and having a melt flow index from about 0.1 g/10 min to about 5 g/10 min, a second ethylene and α-olefin copolymer obtained using a single-site catalyst and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index from higher than about 5 g/10 min to about 20 g/10 min; and a third ethylene and α-olefin copolymer obtained using a single-site catalyst and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index greater than about 20 g/10 min.
Description




TECHNICAL FIELD




This invention relates to a polymer blend for fabricating medical materials and more particularly, to a blend of ethylene and α-olefin copolymers each having a narrow molecular weight distribution for fabricating medical films and tubings.




BACKGROUND ART




In the medical field, where beneficial agents are collected, processed and stored in containers, transported and ultimately delivered through tubes by infusion to patients, there has been a recent trend toward developing materials useful for fabricating such containers and tubing without the disadvantages of currently used materials such as polyvinyl chloride. These new materials for tubings must have a unique combination of properties, so that the tubing may be used in peritoneal dialysis and I.V. administration sets. Among these are the materials must be optically clear, environmentally compatible, have sufficient yield strength and flexibility, have a low quantity of low molecular weight additives, have good dimensional stability and be compatible with medical solutions.




It is desirable for medical tubing to be optically transparent to allow for visual inspection of fluids in the tubing.




It is also a requirement that the tubing materials be environmentally compatible as a significant quantity of medical tubing is disposed of in landfills and through incineration. Further benefits are realized by using a material that is thermoplastically recyclable so that scrap generated during manufacturing may be incorporated into virgin material and refabricated into other useful articles.




For tubing that is disposed of by incineration, it is necessary to use a material that does not generate or minimizes the formation of by-products such as inorganic acids which may be environmentally harmful, irritating, and corrosive. For example, PVC may generate objectionable amounts of hydrogen chloride (or hydrochloric acid when contacted with water) upon incineration.




To be compatible with medical or dialysis solutions, it is desirable that the tubing material be free from or have a minimal content of low molecular weight additives such as plasticizers, stabilizers and the like. These components could be extracted into the dialysis or therapeutic solutions that come into contact with the material. The additives may react with the solutions or otherwise render the solutions ineffective.




Polyvinyl chloride (“PVC”) has been widely used to fabricate medical tubings as it meets most of these requirements. However, because PVC by itself is a rigid polymer, low molecular weight components known as plasticizers must be added to render PVC flexible. As set forth above, these plasticizers may leach out of the tubing and into the fluid passing through the tubing to contaminate the fluid. For this reason, and because of the difficulties encountered in incinerating PVC, there is a need to replace PVC medical tubing.




Polyolefins have been developed which meet many of the requirements of medical containers and tubing, without the disadvantages associated with PVC. Polyolefins typically are compatible with medical applications because they have minimal extractability to the fluids and contents which they contact. Most polyolefins are environmentally sound as they do not generate harmful degradants upon incineration, and in most cases are capable of being thermoplastically recycled. Many polyolefins are cost effective materials that may provide an economic alternative to PVC. However, there are many hurdles to overcome to replace all the favorable attributes of PVC with a polyolefin.




One particular polyolefin of interest is an ethylene and α-olefin copolymer obtained using a single-site catalyst such as a metallocene catalyst, a vanadium catalyst or the like. Of this group of copolymers those having a density of less than about 0.915 g/cc are most desirable due to their favorable modulus of elasticity and other physical characteristics. These copolymers obtained using a single site catalyst shall be referred to as ultra-low density polyethylene (m-ULDPE). The m-ULDPE copolymers have better clarity and softness, a low level of extractables and also have fewer additives than traditional polyolefins. This is largely due to m-ULDPE having a narrow molecular weight distribution and a narrow composition distribution. The m-ULDPE is a newly commercialized resin that recently has been used in food and some medical applications.




The major technical challenges of using m-ULDPE to fabricate medical tubing or films is to overcome a melt fracture phenomenon that readily occurs in these type of polymers during processing. Melt fracture is typically and easily generated in this family of resins because they display significantly less rheological shear thinning during extrusion when compared to other ULDPE resins obtained using traditional Ziegler-Natta type catalysts. Melt fracture occurs when the surface of the extrudate reaches an unstable flow pattern when the extrusion speed exceeds certain levels. The unstable flow pattern leads to a structural and cosmetic defect in the surface of the finished product which is sometimes referred to as “shark skin” due to its textured finish. The melt fracture phenomenon significantly limits the range of output rates in which these resins can be processed without experiencing melt fracture and in most cases the rate falls outside the desired output rate of commercial extrusion processes. The resin industry has attempted to overcome this challenge by introducing fluoro-polymer based processing aids. The use of such processing aids is undesirable in the medical industry as such additives may leach into the solutions or generate inorganic acids upon incineration.




Currently, there are efforts in dealing with melt fracture without introducing foreign additives into the material formulations. One is to raise the melt temperature, but has a potential drawback of widening the dimensional tolerance due to longer cooling period of the extrudate which in turn can lead to dimensional tolerance problems and slow the extrusion rate. Another is to apply surface coat of fluoro-polymer on the die surface to reduce extrusion friction resistance. Both have been proved not effective for fabricating medical products but may be effective in manufacturing other products. Another effort is to blend a variety of polymers. Blending different polymers to achieve desired product performance is commonly used in the plastics industry. However, the impacts of the miscibility of the resins on the mechanical properties are always one of the major criteria in selecting individual polymers before blending. Products with high haze values are usually generated with mismatched resin densities or refractive indicies.




SUMMARY OF THE INVENTION




The present invention provides a blend of m-ULDPE resins or similar resins with a narrow molecular weight distribution for high speed production of medical products such as tubings or films with no melt fracture, good dimensional control, and high production throughput rate.




The present invention provides a polymer blend for fabricating medical products. The blend has a first ethylene and α-olefin copolymer obtained using a single site catalyst present in an amount by weight of from about 0% to about 99% by weight of the blend and having a melt flow index from fractional, such as about 0.1 g/10 min, to about 5 g/10 min, a second ethylene and α-olefin copolymer obtained using a single site catalyst and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index from higher than about 5 g/10 min to about 20 g/10 min; and a third ethylene and α-olefin copolymer obtained using a single-site catalyst and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index greater than about 20 g/10 min.




The present invention further provides a polymer blend for fabricating medical products. The blend has a first ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of from about 0% to about 99% by weight of the blend and having a melt flow index from about 0.1 g/10 min to about 5 g/10 min, a second ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend of from about 0% to about 99% and having a melt flow index from higher than about 5 g/10 min to about 20 g/10 min, and a third ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index greater than about 20 g/10 min.




The present invention further provides a medical tubing having a sidewall of a polymer blend. The blend has a first ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of from about 0% to about 99% by weight of the blend and having a melt flow index from about 0.1 g/10 min to about 5 g/10 min, a second ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend of from about 0% to about 99% and having a melt flow index from higher than about 5 g/10 min to about 20 g/10 min, and a third ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index greater than about 20 g/10 min.




The present invention further provides a medical film of a polymer blend. The polymer blend having a first ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of from about 0% to about 99% by weight of the blend and having a melt flow index from about 0.1 g/10 min to about 5 g/10 min, a second ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend of from about 0% to about 99% and having a melt flow index from higher than about 5 g/10 min to about 20 g/10 min, and a third ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index greater than about 20 g/10 min.











BRIEF DESCRIPTION OF DRAWINGS





FIG. 1

is a cross-sectional view of a monolayer tubing;





FIG. 2

is a cross-sectional view of a multiple layered tubing;





FIG. 3

is a plan view of a multiple lumen tubing;





FIG. 4

is a plan view of a peritoneal dialysis administration set;





FIG. 5

is a cross-sectional view of a monolayer film;





FIG. 6

is cross-sectional view of a multiple layered film; and





FIG. 7

is a perspective view of typical medical tubing clamp for use in I.V. administration sets and peritoneal dialysis administration sets.











DETAILED DESCRIPTION OF THE DRAWINGS




While the invention is susceptible of embodiment in many different forms, there is shown in the drawings and will herein be described in detail preferred embodiments of the invention with the understanding that the present disclosure is to be considered as an exemplification of the principles of the invention and is not intended to limit the broad aspect of the invention to the embodiments illustrated.




The present invention provides non-PVC containing polymer blends for fabricating medical and food product such as tubings, films and containers and the like fabricated therefrom. The blends of the present invention are of olefin containing polymers having a narrow molecular weight distribution. The blends are capable of being processed at the rates required by commercial processing equipment and provide tubings and films having favorable surface characteristics, dimensional stability, modulus of elasticity, softness, optical clarity and yield strength.




The blends of the present invention have at least two polymeric components. In a preferred form of the invention the blends have three or more components.




Suitable polymers of the present invention are selected from ethylene and α-olefin copolymers preferably having a density, as measured by ASTM D-792 of less than about 0.915 g/cc and are commonly referred to as very low density polyethylene (VLDPE), ultra low density ethylene (ULDPE) and the like. The α-olefin should have from 3-17 carbons, more preferably from 4-12 and most preferably 4-8 carbons. In a preferred form of the invention, the ethylene and α-olefin copolymers are obtained using a single-site catalysts. Suitable single-site catalyst systems, among others, are those disclosed in U.S. Pat. Nos. 5,783,638 and 5,272,236. Suitable ethylene and α-olefin copolymers include those sold by Dow Chemical Company under the AFFINITY tradename, Dupont-Dow under the ENGAGE tradename and Exxon under the EXACT tradename.




In preferred form of the invention the components of the blend with have refractive indicies that differ by equal to or less than 0.08, more preferably equal to or less than 0.04 and most preferably equal to or less than 0.01. Also, in a preferred form of the invention, the components of the blend will have a difference in their densities of equal to or less than 0.008 g/cc, more preferably equal to or less than 0.004 g/cc and most preferably equal to or less than 0.002 g/cc.




These m-ULDPE resins have narrow molecular weight distributions. What is meant by molecular weight distribution is M


w


/M


n


where M


w


is the weight average molecular weight and M


n


is the number average molecular weight. What is meant by the term narrow molecular weight distribution is that M


w


/M


n


is less than about 3, more preferably less than about 2.8 and most preferably less than about 2.5




To overcome the difficulty in processing these resins at high speed throughputs the present invention provides blending ULDPE resins having varying melt indicies. The term “melt flow” and “melt flow index” is used herein as the amount, in grams, of a thermoplastic resin which can be forced through a given orifice under a specified pressure and temperature within 10 minutes. The value should be determined in accordance with ASTM D 1238. For two component blends having a first and a second ULDPE the first ULDPE will have a melt index of from 0.1 g/10 min to about 5 g/10 min and the second ULDPE will have a melt flow index of greater than or equal to about 5 g/10 min.




In a preferred form of the invention the blend has a first, second and third ULDPE resin. The first ULDPE resin will have a melt index from about 0.1 g/10 min to about 5 g/10 min, the second ULDPE resin will have a melt index of from higher than about 5 g/10 min to about 20 g/10 min and the third ULDPE resin will have a melt flow index of greater than about 20 g/10 min. The first, second and third ULDPE resins can be present in an amount from about 0% to about 99% by weight of the blend, more preferably from about 5% to about 70% and most preferably in substantially equal amounts by weight.




The blends of the present invention are capable of being fabricated into monolayer tubings (FIG.


1


), multiple layered tubings (FIG.


2


), a multiple lumen tubing (FIG.


3


), monolayer films (

FIG. 5

) and multiple layered films (FIG.


6


).

FIG. 4

shows a peritoneal dialysis administration set


20


having tubing


22


and a container


24


fabricated from the tubing and films of the present invention. The blends can be fabricated at commercial processing rates and provide dimensionally stable products without experiencing the shark skin appearance in the finished product which is indicative of melt fracture.




The tubings shown in

FIGS. 1

,


2


and


3


shall have the following physical properties: a modulus of elasticity of less than about 30,000 psi, more preferably less than about 20,000 and most preferably less than about 10,000 psi, an internal haze of less than about 25% when measured in accordance with ASTM D1003, is capable of being fabricated at a throughput rate of greater than about 100 ft/min, more preferably greater than about 200 ft/min, even more preferably greater than about 300 ft/min and most preferably equal to or greater than about 350 ft/min; has a substantially smooth surface absent a shark skin appearance which is indicative of melt fracture, has less than about 10 mg of low molecular weight extractible components, good dimensional stability, a yield strength of from about 500 psi to about 1000 psi and more preferably from about 600 psi to about 800 psi, is capable of being repeatedly used with a medical tubing clamp with an occlusion force typically of about 5 lbs without significantly damaging the tubing and is capable of solvent bonding to a rigid component.




What is meant by “smooth surface” is that the surface of the tubing or film does not have a substantial of significant quantity of imperfections known in the field as “shark skin.” The tubing or film is smooth to the touch and smooth in appearance to the naked eye. This can be quantified by a melt fracture number as follows: 1 tubing turns opaque and displays severe shark skin pattern, 2 tubing is translucent and shark skin appearance is obvious, 3 tubing is clear with light shark skin appearance, and 4 tubing is clear with no shark skin appearance.




What is meant by “low molecular weight extractible component” is the amount of material extracted from a 635 cm


2


piece of test material extracted at 70° C. for 24 hours in 106 ml of USP purified water.




What is meant by the term “yield strength” is the quantity resulting from dividing the load point by the original cross-sectional thickness area of the specimen and measured according to ASTM D-882.




What is meant by the term “good dimensional stability” is that the process capability C


P


of the inner diameter of the tubing (I.D.), the outer diameter (O.D.) and the tubing wall thickness shall be greater than about 1.33 for a dimensional tolerance of +/−1.7% of O.D., 2.5% of I.D., and 10% of wall thickness. C


P


is the specification width (or the range between upper and lower specification limits) divided by the process width (or 6 times the standard deviation). The C


P


is measured on-line by a BETA LAZERMIKE Model 163-100-05.




The tubing of the present invention can be used with a medical tubing clamp such as the ones shown in

FIG. 7. A

medical tubing clamp


50


is used to control the flow rate of fluid passing through the medical tubing. The medical tubing clamp


52


has a slot


54


through which the tubing is placed. The slot


54


narrows from a diameter greater than the O.D. of the tubing to a point smaller than the O.D. of the tubing. By moving the tubing in the slot the tubing sidewalls can occlude the flow of fluid through the tubing. The tubing must have sufficient lubricity for the clamp to be used without severing the tubing or without permanently occluding the tubing under a typical occluding force applied by the claim of about 5 lbs.




What is meant by the term solvent bonding is that the tubing can be exposed to a solvent to melt, dissolve or swell the tubing and then be attached to another polymeric component to form a permanent bond. Suitable solvents typically include those having a solubility parameter of less than about 20 (MPa)


½


, more preferably less than about 19 (MPa)


½


and most preferably less than about 18 (MPa)


½


and include, but are not limited to, aliphatic hydrocarbons, aromatic hydrocarbons, mixtures of aliphatic hydrocarbons, mixtures of aromatic hydrocarbons and mixtures of aromatic and aliphatic hydrocarbons. Suitable aliphatic hydrocarbons include substituted and unsubstituted hexane, heptane, cyclohexane, cycloheptane, decalin, and the like. Suitable aromatic hydrocarbons include substituted and unsubstituted aromatic hydrocarbon solvents such as xylene, tetralin, toluene, and cumene. Suitable hydrocarbon substituents include aliphatic substituents having from 1-12 carbons and include propyl, ethyl, butyl, hexyl, tertiary butyl, isobutyl and combinations of the same. What is meant by the terms “aliphatic hydrocarbon” and “aromatic hydrocarbon” is a compound containing only carbon and hydrogen atoms. Suitable solvents will also have a molecular weight less than about 200 g/mole, more preferably less than about 180 g/mole and most preferably less than about 140 g/mole.




What is meant by a “rigid component” is a connector or other device commonly used in peritoneal dialysis or I.V. administration sets and typically having a modulus of elasticity of greater than about 30,000 psi. Suitable polymers for fabricating a rigid component includes homopolymers and copolymers of polypropylenes, polyesters, polyamdies, polycarbonates, cylic olefin containing polymers and bridged polycyclic olefin containing polymers. Suitable cyclic olefin containing polymers and bridged polycylic olefin containing polymers are disclosed in U.S. patent application Nos. 09/393,912, 09/393,052, 09/393,051 which are incorporated herein by reference and made a part hereof.




The film shown in

FIGS. 5 and 6

shall have the following physical characteristics measured in accordance with the details provided above: a modulus of elasticity of less than about 30,000 psi, an internal haze of less than about 25%, capable of being fabricated at a throughput rate of greater than about 300 ft/min, more preferably greater than about 400 ft/min and most preferably greater than about 500 ft/min; has a substantially smooth surface absent of a shark skin appearance, good dimensional stability, has less than about 10 mg of low molecular weight extractible components, and a yield strength of from about 500 psi to about 1000 psi and more preferably from about 600 psi to about 800 psi.




The blends of the present invention can be provided individually and blended by tumble blending or using standard Banburry type mixers, or twin screw type mixers. It is also contemplated that the desired components can be blended, extruded and pellitized. It is also contemplated to prepare the desired blend of resins using series of reactors connected in sequence.




In a preferred form of the invention for the latter described process, there is a reactor provided for each of the polymers in the blend. Monomers and catalyst are added into the first reactor. The reaction conditions, particularly pressure, temperature, and residence time, are controlled so that the amount of product produced in each reactor is within certain limits and the product has certain properties. The catalyst used in each reactor is a metallocene catalyst or a blend with other metallocene catalyst or a blend with other catalyst. In the first reaction step, ethylene monomer, α-olefin comonomer, and catalyst are introduced into the first reactor.




In the first reactor, a ULDPE is produced with a melt flow index of from about 0.1 g/10 min to about 5 g/10 min. The ULDPE product and the unreacted monomers are transported to the second reactor. In the second reactor, additional ULDPE resin is produced with a melt flow index of greater than about 5 g/10 min to about 20 g/10 min. The two types of ULDPE polymers and the unreacted monomers are transported to the third reactor. In the final reactor, additional resin is produced with a melt flow index of greater than about 20 g/10 min. Each of the three reactor products will be present in the final product in an amount from about 0% to about 99% by weight of the blend, more preferably from about 5% to about 90%, and most preferably in substantially equal portions. Of course it is possible to produce the polymers in any sequence so that the higher melt flow index polymer is produced in the first, second or third reactor. The same is true for the other components. It is also possible to produce two components with two reactors or to produce more than 3 components as desired.




The use of multistage processes for polymerization to produce blends of resins of different molecular weights is well known. For example, U.S. Pat. No. 4,336,352 concerned polyethylene compositions consisting of three different polyethylenes. One alternative presented contains a three stage process. In the first stage polyethylene having a density between 0.94-0.98 g/cc is polymerized and the proportion of this fraction to the end product is 1-10%. In the next polymerization stage polyethylene having a density between 0.94-0.98 is produced. In the third polymerization step polyethylene having a density of 0.90-0.97 is produced. The final product has a melt index of 0.001-1 and a density of 0.935-0.976.




The blends can be fabricated into tubing using standard polymer processing techniques such as extrusion, coextrusion, blow extrusion, blow molding, injection molding and the like. Similarly the blends can be fabricated into films or sheetings using standard polymer processing techniques such as extrusion, coextrusion, blow extrusion, blow molding, compression molding injection molding, lamination, thermoforming, calendaring and the like.




The following are non-limiting examples of the present invention and should not be used to limit the scope of the claims set forth below.




EXAMPLES




The following m-ULDPE resins were used in fabricating two and three component blends.






























Ulti-




Ulti-







Re-







Hard-





mate




mate







frac-





Den-




MI




ness




DSC




Tensile




Elonga-






Ma-




tive





sity




(g/10




Shore




Tm




strength




tion






terials




index




MWD




(g/cc)




min)




A




(° C.)




(Mpa)




(%)































Engage




1.501




2.39




0.885




1.0




86




76




30.3




700






8003














(A)














Engage




1.501




2.33




0.880




18




76




78




10.6




1000






8411














(B)














Engage




1.501




2.15




0.885




30




85




76




10.8




>1000






8401














(C)














The two and three component blends in the amounts specified in the table below were fabricated into medical tubings. The medical tubings had the noted physical characteristics.























MI













(g/10








Cp of








min)




Melt





Cp




Cp




wall




Melt







of the




Temp




Speed




of




of




thick-




frac-






Resin Blend




blend




(° F.)




(FTPM)




I.D.




O.D.




ness




ture






























  75% A +




1.56




348




200




0.74




0.74




2.22




1






  25% C













  50% A +




5




347




200




1.10




1.10




4.43




2






  50% C













  45% A+




3




346




200




1.33




1.33




4.43




2






  45% B+













  10% C













  45% A +




3




346




250




0.70




0.84




2.95




2






  45% B +













  10% C













  33% A +




6.5




343




200




1.66




1.66




4.43




4






  33% B +













  33% C













  33% A +




6.5




333




350




1.66




1.90




4.43




4






  33% B +













+33% C














While specific embodiments have been illustrated and described, numerous modifications are possible without departing from the spirit of the invention, and the scope of protection is only limited by the scope of the accompanying claims.



Claims
  • 1. A polymer blend for fabricating medical products comprising:a first ethylene and α-olefin copolymer obtained using a single-site catalyst present in an amount by weight of from about 0% to about 99% by weight of the blend and having a melt flow index from about 0.1 g/10 min to about 5 g/10 min; a second ethylene and α-olefin copolymer obtained using a single-site catalyst and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index from higher than about 5 g/10 min to about 20 g/10 min; and a third ethylene and α-olefin copolymer obtained using a single-site catalyst and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index greater than about 20 g/10 min.
  • 2. The blend of claim 1 wherein the first, second hand third ethylene and α-olefin copolymers are each present in an amount within the range of from about 5% to about 70% by weight of the blend.
  • 3. The blend of claim 2 wherein the first, second and third ethylene and α-olefin copolymers are each present in substantially equal quantities by weight of the blend.
  • 4. The blend of claim 1 when fabricated into a monolayer tubing has a modulus of elasticity of less than about 30,000 psi.
  • 5. The blend of claim 1 when fabricated into a monolayer tubing has a modulus of elasticity of less than about 20,000 psi.
  • 6. The blend of claim 1 when fabricated into a monolayer tubing has a modulus of elasticity of less than about 10,000 psi.
  • 7. The blend of claim 4 when fabricated into a monolayer tubing has an internal haze less than about 25%.
  • 8. The blend of 7 is capable of being fabricated into a monolayer tubing at a throughput rate of greater than about 100 ft/min.
  • 9. The blend of 7 is capable of being fabricated into a monolayer tubing at a throughput rate of greater than about 200 fl/min.
  • 10. The blend of 7 is capable of being fabricated into a monolayer tubing at a throughput rate of greater than about 300 ft/min.
  • 11. The blend of 7 is capable of being fabricated into a monolayer tubing at a throughput rate of greater than about 350 ft/min.
  • 12. The blend of claim 8 when fabricated into a monolayer tubing has a substantially smooth surface.
  • 13. The blend of claim 1 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.08.
  • 14. The blend of claim 1 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.04.
  • 15. The blend of claim 1 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.01.
  • 16. The blend of claim 1 when fabricated into a monolayer tubing has less than about 10 mg of low molecular weight extractible components.
  • 17. The blend of claim 1 when fabricated into a monolayer tubing has a yield strength within the range of from about 500 psi to about 1000 psi.
  • 18. The blend of claim 1 when fabricated into a monolayer tubing has a yield strength of from about 600 psi to about 1000 psi.
  • 19. The blend of claim 1 when fabricated into a monolayer tubing is capable of being used with a medical tubing clamp without significantly damaging the tubing.
  • 20. The blend of claim 1 when fabricated into a monolayer tubing is capable of solvent bonding to a rigid component.
  • 21. The blend of claim 20 wherein the rigid component is fabricated from a cyclic olefin containing polymer or a bridged polycyclic hydrocarbon containing polymer.
  • 22. The blend of claim 1 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.008 g/cc.
  • 23. The blend of claim 1 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.004 g/cc.
  • 24. The blend of claim 1 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.002 g/cc.
  • 25. The blend of claim 1 wherein the process capability of the blend shall be greater than about 1.33 for a dimensional tolerance of +/−1.7%.
  • 26. A polymer blend for fabricating medical products comprising:a first ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of from about 0% to about 99% by weight of the blend and having a melt flow index from about 0.1 g/10 min to about 5 g/10 min; a second ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend of from about 0% to about 99% and having a melt flow index from higher than about 5 g/10 min to about 20 g/10 min; and a third ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index greater than about 20 g/10 min.
  • 27. The blend of claim 26 wherein the first, second and third ethylene and α-olefin copolymers have a molecular weight distribution of less than about 2.8.
  • 28. The blend of claim 26 wherein the first, second and third ethylene and α-olefin copolymers have a molecular weight distribution of less than about 2.5.
  • 29. The blend of claim 26 wherein the first, second and third ethylene and α-olefin copolymers are obtained using a single-site catalyst.
  • 30. The blend of claim 26 wherein the first, second and third ethylene and α-olefin copolymers are each present in an amount within the range of from about 5% to about 70% by weight of the blend.
  • 31. The blend of claim 26 wherein the first, second and third ethylene and α-olefin copolymers are each present in substantially equal quantities by weight of the blend.
  • 32. The blend of claim 26 when fabricated into a monolayer tubing has a modulus of elasticity of less than about 30,000 psi.
  • 33. The blend of claim 26 when fabricated into a monolayer tubing has a modulus of elasticity of less than about 20,000 psi.
  • 34. The blend of claim 26 when fabricated into a monolayer tubing has a modulus of elasticity of less than about 10,000 psi.
  • 35. The blend of claim 26 when fabricated into a monolayer tubing has an internal haze less than about 25%.
  • 36. The blend of claim 26 is capable of being fabricated into a monolayer tubing at a throughput rate of greater than about 100 ft/min.
  • 37. The blend of claim 26 is capable of being fabricated into a monolayer tubing at a throughput rate of greater than about 200 ft/min.
  • 38. The blend of claim 27 is capable of being fabricated into a monolayer tubing at a throughput rate of greater than about 300 ft/min.
  • 39. The blend of claim 26 is capable of being fabricated into a monolayer tubing at a throughput rate of greater than about 350 ft/min.
  • 40. The blend of claim 26 when fabricated into a monolayer tubing has a substantially smooth surface.
  • 41. The blend of claim 26 when fabricated into a monolayer tubing has less than about 10 mg of low molecular weight extractible components.
  • 42. The blend of claim 26 when fabricated into a monolayer tubing has a yield strength within the range of from about 500 psi to about 1000 psi.
  • 43. The blend of claim 26 when fabricated into a monolayer tubing has a yield strength of from about 600 psi to about 1000 psi.
  • 44. The blend of claim 26 when fabricated into a monolayer tubing is capable of being used with a medical tubing clamp without significantly damaging the tubing.
  • 45. The blend of claim 26 when fabricated into a monolayer tubing is capable of solvent bonding to a rigid component.
  • 46. The blend of claim 45 wherein the rigid component is fabricated from a cyclic olefin containing polymer or a bridged polycyclic hydrocarbon containing polymer.
  • 47. The blend of claim 26 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.08.
  • 48. The blend of claim 26 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.04.
  • 49. The blend of claim 26 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.01.
  • 50. The blend of claim 26 wherein the process capability of the blend shall be greater than about 1.33 for a dimensional tolerance of +/−1.7%.
  • 51. The blend of claim 26 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.008 g/cc.
  • 52. The blend of claim 26 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.004 g/cc.
  • 53. The blend of claim 26 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.002 g/cc.
  • 54. A medical tubing comprising:a sidewall of a polymer blend comprising a first ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of from about 0% to about 99% by weight of the blend and having a melt flow index from about 0.1 g/10 min to about 5 g/10 min, a second ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend of from about 0% to about 99% and having a melt flow index from higher than about 5 g/10 min to about 20 g/10 min, and a third ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index greater than about 20 g/10 min.
  • 55. The tubing of claim 54 wherein the first, second and third ethylene and α-olefin copolymers have a molecular weight distribution of less than about 2.8.
  • 56. The tubing of claim 54 wherein the first, second and third ethylene and α-olefin copolymers have a molecular weight distribution of less than about 2.5.
  • 57. The tubing of claim 54 wherein the first, second and third ethylene and α-olefin copolymers are obtained using a single-site catalyst.
  • 58. The tubing of claim 54 wherein the first, second and third ethylene and α-olefin copolymers are each present in an amount within the range of from about 5% to about 70% by weight of the blend.
  • 59. The tubing of claim 54 wherein the first, second and third ethylene and α-olefin copolymers are each present in substantially equal quantities by weight of the blend.
  • 60. The tubing of claim 54 having a modulus of elasticity of less than about 30,000 psi.
  • 61. The tubing of claim 54 having a modulus of elasticity of less than about 20,000 psi.
  • 62. The tubing of claim 54 having a modulus of elasticity of less than about 10,000 psi.
  • 63. The tubing of claim 54 having an internal haze less than about 25%.
  • 64. The tubing of claim 54 is capable of being fabricated at a throughput rate of greater than about 100 ft/min.
  • 65. The tubing of claim 54 is capable of being fabricated at a throughput rate of greater than about 200 ft/min.
  • 66. The tubing of claim 54 is capable of being fabricated at a throughput rate of greater than about 300 ft/min.
  • 67. The tubing of claim 54 is capable of being fabricated at a throughput rate of greater than about 350 ft/min.
  • 68. The tubing of claim 54 has a substantially smooth surface.
  • 69. The tubing of claim 54 having less than about 10 mg of low molecular weight extractible components.
  • 70. The tubing of claim 54 having a yield strength within the range of from about 500 psi to about 1000 psi.
  • 71. The tubing of claim 54 having a yield strength of from about 600 psi to about 1000 psi.
  • 72. The tubing of claim 54 is capable of being used with a medical tubing clamp without significantly damaging the tubing.
  • 73. The tubing of claim 54 is capable of solvent bonding to a rigid component.
  • 74. The tubing of claim 73 wherein the rigid component is fabricated from a cyclic olefin containing polymer or a bridged polycyclic hydrocarbon containing polymer.
  • 75. The tubing of claim 54 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.08.
  • 76. The tubing of claim 54 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.04.
  • 77. The tubing of claim 54 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.01.
  • 78. The tubing of claim 54 wherein the process capability of the tubing shall be greater than about 1.33 for a dimensional tolerance of +/−1.7%.
  • 79. The tubing of claim 54 is a monolayer tubing.
  • 80. The tubing of claim 54 is a multiple layered tubing wherein the blend defines a layer within the multiple layered tubing.
  • 81. The tubing of claim 54 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.008 g/cc.
  • 82. The tubing of claim 54 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.004 g/cc.
  • 83. The tubing of claim 54 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.002 g/cc.
  • 84. A medical film comprising:a polymer blend comprising a first ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of from about 0% to about 99% by weight of the blend and having a melt flow index from about 0.1 g/10 min to about 5 g/10 min, a second ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend of from about 0% to about 99% and having a melt flow index from higher than about 5 g/10 min to about 20 g/10 min, and a third ethylene and α-olefin copolymer having a molecular weight distribution of less than about 3 and being present in an amount by weight of the blend from about 0% to about 99% and having a melt flow index greater than about 20 g/10 min.
  • 85. The film of claim 84 wherein the first, second and third ethylene and α-olefin copolymers have a molecular weight distribution of less than about 2.8.
  • 86. The film of claim 84 wherein the first, second and third ethylene and α-olefin copolymers have a molecular weight distribution of less than about 2.5.
  • 87. The film of claim 84 wherein the first, second and third ethylene and α-olefin copolymers are obtained using a single-site catalyst.
  • 88. The film of claim 84 wherein the first, second and third ethylene and α-olefin copolymers are each present in an amount within the range of from about 5% to about 70% by weight of the blend.
  • 89. The film of claim 84 wherein the first, second and third ethylene and α-olefin copolymers are each present in substantially equal quantities by weight of the blend.
  • 90. The film of claim 84 having a modulus of elasticity of less than about 30,000 psi.
  • 91. The film of claim 84 having an internal haze less than about 25%.
  • 92. The film of claim 84 is capable of being fabricated at a throughput rate of greater than about 300 ft/min.
  • 93. The film of claim 84 is capable of being fabricated at a throughput rate of greater than about 400 ft/min.
  • 94. The film of claim 84 is capable of being fabricated at a throughput rate of greater than about 500 ft/min.
  • 95. The film of claim 84 has a substantially smooth surface.
  • 96. The film of claim 84 having less than about 10 mg of low molecular weight extractible components.
  • 97. The film of claim 84 having a yield strength of from about 500 psi to about 1000 psi.
  • 98. The film of claim 84 is capable of being solvent bonded.
  • 99. The film of claim 84 is a monolayer film.
  • 100. The film of claim 84 is a multiple layered film wherein the blend defines a layer within the multiple layered film.
  • 101. The film of claim 84 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.08.
  • 102. The film of claim 84 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.04.
  • 103. The film of claim 84 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a refractive index with the refractive indicies differing by equal to or less than 0.01.
  • 104. The film of claim 84 wherein the process capability of the film shall be greater than about 1.33 for a dimensional tolerance of +/−1.7%.
  • 105. The film of claim 84 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.008 g/cc.
  • 106. The film of claim 84 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.004 g/cc.
  • 107. The film of claim 84 wherein the first ethylene and α-olefin copolymer, the second ethylene and α-olefin copolymer and the third ethylene and α-olefin copolymer each have a density differing by equal to or less than 0.002 g/cc.
US Referenced Citations (192)
Number Name Date Kind
2705223 Renfrew et al. Mar 1955 A
2971876 Phair Feb 1961 A
3255923 Soto Jun 1966 A
3375300 Ropp Mar 1968 A
3494897 Reading et al. Feb 1970 A
3514359 Frese May 1970 A
3772136 Workman Nov 1973 A
3912843 Brazier Oct 1975 A
3937758 Castagna Feb 1976 A
3995084 Berger et al. Nov 1976 A
4041103 Davison et al. Aug 1977 A
4058647 Inoue et al. Nov 1977 A
4087587 Shida et al. May 1978 A
4087588 Shida et al. May 1978 A
4095012 Schirmer Jun 1978 A
4110303 Gergen et al. Aug 1978 A
4147827 Breidt, Jr. et al. Apr 1979 A
4233367 Ticknor et al. Nov 1980 A
4322465 Webster Mar 1982 A
4322480 Tuller et al. Mar 1982 A
4327726 Kwong May 1982 A
4332655 Berejka Jun 1982 A
4336352 Sakurai et al. Jun 1982 A
4387184 Coquard et al. Jun 1983 A
4405667 Christensen et al. Sep 1983 A
4407877 Rasmussen Oct 1983 A
4407888 Crofts Oct 1983 A
4417753 Bacebowski et al. Nov 1983 A
4429076 Saito et al. Jan 1984 A
4479989 Mahal Oct 1984 A
4521437 Storms Jun 1985 A
4548348 Clements Oct 1985 A
4562118 Maruhashi et al. Dec 1985 A
4568723 Lu Feb 1986 A
4573994 Fischell et al. Mar 1986 A
4588648 Krueger et al. May 1986 A
4599276 Martini Jul 1986 A
4627844 Schmitt Dec 1986 A
4628969 Jurgens, Jr. et al. Dec 1986 A
4636412 Field Jan 1987 A
4640870 Akazawa et al. Feb 1987 A
4643926 Mueller Feb 1987 A
4686125 Johnston et al. Aug 1987 A
4692361 Johnson et al. Sep 1987 A
4707389 Ward Nov 1987 A
4724028 Zabielski et al. Feb 1988 A
4726997 Mueller et al. Feb 1988 A
4732795 Ohya et al. Mar 1988 A
4734327 Vicik Mar 1988 A
4735855 Wofford et al. Apr 1988 A
4740582 Coquard et al. Apr 1988 A
4753222 Morishita Jun 1988 A
4760114 Haaf et al. Jul 1988 A
4764404 Genske et al. Aug 1988 A
4767651 Starczewski et al. Aug 1988 A
4772497 Maasola Sep 1988 A
4778697 Genske et al. Oct 1988 A
4792488 Schirmer Dec 1988 A
4795782 Lutz et al. Jan 1989 A
4800129 Deak Jan 1989 A
4803102 Raniere et al. Feb 1989 A
4834755 Silvestrini et al. May 1989 A
4855356 Holub et al. Aug 1989 A
4856259 Woo et al. Aug 1989 A
4856260 Woo et al. Aug 1989 A
4863996 Nakazima et al. Sep 1989 A
4871799 Kobayashi et al. Oct 1989 A
4873287 Sauers et al. Oct 1989 A
4877682 Raniere et al. Oct 1989 A
4885119 Mueller et al. Dec 1989 A
4910085 Gogolewski et al. Mar 1990 A
4923470 Dumican May 1990 A
4929479 Shishido et al. May 1990 A
4931520 Yamanashi et al. Jun 1990 A
4957966 Nishio et al. Sep 1990 A
4957967 Mizuno et al. Sep 1990 A
4966795 Genske et al. Oct 1990 A
4977213 Giroud-Abel et al. Dec 1990 A
4992511 Yamamoto et al. Feb 1991 A
4996054 Pietsch et al. Feb 1991 A
4999254 Ofstein Mar 1991 A
5003019 Ishimaru et al. Mar 1991 A
5006601 Lutz et al. Apr 1991 A
5008356 Ishimaru et al. Apr 1991 A
5017652 Abe et al. May 1991 A
5034457 Serini et al. Jul 1991 A
5034458 Serini et al. Jul 1991 A
5053457 Lee Oct 1991 A
5071686 Genske et al. Dec 1991 A
5071911 Furuta et al. Dec 1991 A
5071912 Furuta et al. Dec 1991 A
5075376 Furuta et al. Dec 1991 A
5079295 Furuta et al. Jan 1992 A
5085649 Flynn Feb 1992 A
5087677 Brekner et al. Feb 1992 A
5093164 Bauer et al. Mar 1992 A
5093194 Touhsaent et al. Mar 1992 A
5094921 Itamura et al. Mar 1992 A
5108844 Blemberg et al. Apr 1992 A
5110642 Genske May 1992 A
5116906 Mizuno et al. May 1992 A
5129894 Sommermeyer et al. Jul 1992 A
5132363 Furuta et al. Jul 1992 A
5135785 Millon Aug 1992 A
5145731 Lund et al. Sep 1992 A
5154979 Kerschbaumer et al. Oct 1992 A
5159004 Furuta et al. Oct 1992 A
5164267 D'Heur et al. Nov 1992 A
5176634 Smith et al. Jan 1993 A
5176956 Jevne et al. Jan 1993 A
5183706 Bekele Feb 1993 A
5185189 Stenger et al. Feb 1993 A
5189091 Laughner Feb 1993 A
5194316 Horner et al. Mar 1993 A
5196254 Akiyama Mar 1993 A
5206290 Mizuno et al. Apr 1993 A
5207983 Liebert et al. May 1993 A
5212238 Schelbelhoffer et al. May 1993 A
5218048 Abe et al. Jun 1993 A
5218049 Yamamoto et al. Jun 1993 A
5230934 Sakano et al. Jul 1993 A
5230935 Delimoy et al. Jul 1993 A
5238997 Bauer et al. Aug 1993 A
5244971 Dekoninck Sep 1993 A
5258230 LaFleur et al. Nov 1993 A
5272235 Wakatsuru et al. Dec 1993 A
5278231 Chundury Jan 1994 A
5288560 Sudo et al. Feb 1994 A
5288799 Schmid et al. Feb 1994 A
5290856 Okamoto et al. Mar 1994 A
5306542 Bayer Apr 1994 A
5312867 Mitsuno et al. May 1994 A
5317059 Chundury et al. May 1994 A
5331057 Brekner et al. Jul 1994 A
5342886 Glotin et al. Aug 1994 A
5348794 Takahashi et al. Sep 1994 A
5356676 von Widdern et al. Oct 1994 A
5359001 Epple et al. Oct 1994 A
5371151 Gelles et al. Dec 1994 A
5378543 Murata et al. Jan 1995 A
5378800 Mok et al. Jan 1995 A
5382631 Stehling et al. Jan 1995 A
5387645 Montag et al. Feb 1995 A
5422409 Brekner et al. Jun 1995 A
5457249 Toshihiro et al. Oct 1995 A
5475060 Brekner et al. Dec 1995 A
5498677 Wellner et al. Mar 1996 A
5534606 Bennett et al. Jul 1996 A
5552504 Bennett et al. Sep 1996 A
5583192 Bennett et al. Dec 1996 A
5610253 Hatke et al. Mar 1997 A
5620425 Heffernan et al. Apr 1997 A
5629398 Okamoto et al. May 1997 A
5637100 Sudo Jun 1997 A
5637400 Brekner et al. Jun 1997 A
5650471 Abe et al. Jul 1997 A
5686527 Laurin et al. Nov 1997 A
5693728 Okamoto et al. Dec 1997 A
5698645 Weller et al. Dec 1997 A
5707751 Garza et al. Jan 1998 A
5723189 Sudo Mar 1998 A
5733991 Rohrmann et al. Mar 1998 A
5744664 Brekner et al. Apr 1998 A
5756623 Krueder et al. May 1998 A
5788670 Reinhard et al. Aug 1998 A
5792824 Natori Aug 1998 A
5795945 Natori Aug 1998 A
5849843 Laurin et al. Dec 1998 A
5854347 Laurin et al. Dec 1998 A
5854349 Abe et al. Dec 1998 A
5863986 Herrmann-Schönherr et al. Jan 1999 A
5872201 Cheung et al. Feb 1999 A
5980495 Heinz et al. Nov 1999 A
5990254 Weller et al. Nov 1999 A
5993949 Rosenbaum et al. Nov 1999 A
5998019 Rosenbaum et al. Dec 1999 A
6007520 Sudo Dec 1999 A
6020444 Riedel et al. Feb 2000 A
6060572 Gillis et al. May 2000 A
6065270 Reinhard et al. May 2000 A
6068936 Peiffer et al. May 2000 A
6110549 Hamada et al. Aug 2000 A
6121394 Sugimoto et al. Sep 2000 A
6136744 Gillis et al. Oct 2000 A
6147025 Gillis et al. Nov 2000 A
6168862 Rosenbaum et al. Jan 2001 B1
6169052 Brekner Jan 2001 B1
6261655 Rosenbaum et al. Jan 2001 B1
6225426 Gillis et al. May 2001 B1
6225427 Burton et al. May 2001 B1
RE37208 Winter et al. Jun 2001 E
6255396 Ding et al. Jul 2001 B1
Foreign Referenced Citations (34)
Number Date Country
251 904 Dec 1987 DE
39 37 865 Jun 1990 DE
41 42 271 Jun 1993 DE
92897 Feb 1983 EP
0 156 464 Oct 1985 EP
0 216 509 Aug 1986 EP
0 283 164 Mar 1988 EP
0 291 208 Apr 1988 EP
0 291 208 Nov 1988 EP
0 492 982 Dec 1991 EP
0 497 567 Jan 1992 EP
0 524 802 Jan 1993 EP
446505 Jun 1993 EP
0 582 355 Feb 1994 EP
0 680 401 Nov 1995 EP
0 430 585 Jan 1996 EP
0 156 464 May 1996 EP
0 709 105 May 1996 EP
0 203 799 Aug 1996 EP
0 384 694 Sep 1996 EP
0 497 567 Sep 1996 EP
0 790 063 Aug 1997 EP
2688511 Sep 1993 FR
2 177 974 Feb 1987 GB
03095286 Apr 1991 JP
05277154 Oct 1993 JP
11071554 Mar 1999 JP
WO8300158 Jan 1983 WO
WO 8607010 Dec 1986 WO
WO 93 23 093 Nov 1993 WO
WO 9708054 Jun 1997 WO
WO 9827926 Feb 1998 WO
9844043 Oct 1998 WO
9848990 Sep 1999 WO